By analyzing 498 cases of differentially expressed prostate cancer genes in TCGA, Chen et al. found that TMED2 and TMED10 were downregulated in prostate cancer tissues and were biomarkers of good prognosis, as their high expression was linked to good OS in prostate cancer patients, revealing the potential role of TMED2 and TMED10 in prostate development, prognosis, and possible treatment75. This evidence concerns the gene TMED2 and prostate carcinoma.